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ABSTRACT   
Primary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying 
disorder with a wide spectrum of motor, cognitive and neuropsychiatric symptoms. It is 
typically inherited as an autosomal dominant trait with four causative genes identified so far: 
SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of 
these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for 
primary brain calcification regardless of their family history. Sequence variants were 
classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the 
ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either 
pathogenic or likely pathogenic variants (n=34, 19.2%) or VUS (n=11, 6.2%). SLC20A2 
provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and 
PDGFRB (1.7%). 81.5% of carriers were symptomatic and the most recurrent symptoms 
were parkinsonism (54.5% of symptomatic patients), cognitive impairment and psychiatric 
disturbances (43.2% each), with a wide range of age at onset (from childhood to 81 years). 
While the pathogenic and likely pathogenic variants identified in this study can be used for 
genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated 
patients, in order to be classified as pathogenic. 
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INTRODUCTION 
Primary familial brain calcification (PFBC) is a rare neuropsychiatric disorder characterized 
by abnormal calcium-phosphate deposits in the microvessels of the basal ganglia and other 
brain regions. Clinical manifestations can start at any age (median 31 years, range 6-77 
years),1 and include a wide spectrum of movement disorders (dystonia, parkinsonism, tremor, 
chorea), neuropsychiatric symptoms (behavioral disturbances, psychosis, mood disorder, 
cognitive impairment), cerebellar signs and other symptoms,2 while up to 42% of the patients 
remain asymptomatic.1 Even though the clinical presentation is variable, the 
neuroradiological picture (evidence of bilateral calcification affecting at least the basal 
ganglia) is thought to be invariably present by the age of 50. Hence, the diagnosis relies on a 
computerized tomography (CT) scan, in absence of other known causes of brain 
calcification.2 PFBC is typically inherited as an autosomal dominant trait, and to date four 
causative genes have been identified.  
 SLC20A2 (solute carrier family 20, member 2) was the first gene to be linked to PFBC.3 
Since its discovery, many protein-truncating and deleterious missense variants have been 
identified, accounting for up to 40% of the familial cases.4 SLC20A2 encodes the 
transmembrane sodium-inorganic phosphate cotransporter PiT2, suggested to have a role in 
phosphate clearance from the cerebrospinal fluid by recent in vitro and knockout mice 
studies.5 
Variants in the PDGFRB gene,6-8 encoding the platelet-derived growth factor receptor β 
(PDGF-Rβ), and in the PDGFB gene (PDGF-Rβ’s main ligand),9-12 have been reported in 
more than 20 unrelated probands so far. PDGFB-PDGF-Rβ signaling mediates survival, 
differentiation and migration of mesenchymal cells, including the vascular smooth muscle 
cells affected by calcifications in PFBC.13 While increased signaling is associated with 
cancers, overgrowth and progeria syndromes,14-18 in PFBC patients protein-truncating 
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PDGFB and missense PDGFB and PDGFRB variants lead to decreased PDGFB-PDGF-Rβ 
signaling.8,19,20 Although PDGFB-PDGF-Rβ signaling is implicated in the regulation of 
inorganic phosphate transport,21 the mechanisms leading to microvascular calcification 
remain unknown.19  
More recently, missense variants in another phosphate transporter, encoded by the XPR1 
gene, were identified in several PFBC families.22 Subsequent functional studies showed that 
XPR1 mutant proteins had severely reduced membrane localization and/or impaired 
phosphate efflux activity.22,23 
The interpretation of sequence variants identified in genetic screens for rare diseases remains 
challenging. The American College of Medical Genetics and Genomics and the Association 
for Molecular Pathology (ACMG-AMP) recently established a set of guidelines to classify 
genetic variants into five categories from benign (1) to pathogenic (5).24 While large 
sequence variant databases, such as gnomAD,25 are helpful in estimating allele frequencies in 
control populations, for rare diseases with incomplete penetrance (such as PFBC) variant 
recurrence in unrelated patients and family segregation data remain critical for interpretation.  
In an international effort, four centers from France, USA, Italy, and Brazil gathered and 
analyzed sequence data from the four genes known to cause autosomal-dominant PFBC. 
 
MATERIAL AND METHODS 
Patients. We included patients with brain calcification that were referred to four centers of 
expertise: University of California, Los Angeles, USA; IRCCS Neurological Institute C. 
Besta, Milan, Italy; Inserm U1245, Rouen, France; and Universidade Federal de Pernambuco, 
Recife, Brazil. All patients presented calcifications affecting at least both lenticular nuclei, 
beyond the age-specific severity threshold,7 a normal phospho-calcic assessment (including at 
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least calcium, phosphate and PTH) in blood, and no other known etiology. Probands and, if 
available, family members underwent clinical examination and blood sampling. Details on 
clinical and family history were obtained by direct interview and/or by reviewing medical 
records. All individuals included in this study had a brain CT scan; for some, however, details 
about the extent and localization of brain calcifications were not available. Detailed inclusion 
criteria are reported in Supplementary Methods. All participants signed written informed 
consent for genetic analyses. 
Genetic screening. Genomic DNA was extracted from peripheral blood by standard methods. 
For samples from the French, US and Brazilian series, PCR amplification and subsequent 
Sanger sequencing of all protein-coding exons and exon-intron boundaries of SLC20A2, 
PDGFB, PDGFRB and XPR1 genes was performed as previously described.3,6,9,22 All 49 
patients from the Italian series were screened with a customized gene panel (Nextera Rapid 
Capture Custom Enrichment), which included the PFBC genes and 55 additional genes 
responsible for diseases characterized by cerebral calcification (Supplementary Methods). 
The following genomic and transcript references were used for variant nomenclature and 
exon numbering: NG_032161.1 and NM_006749.4 for SLC20A2, NG_012111.1 and 
NM_002608.2 for PDGFB, NG_023367.1 and NM_002609.3 for PDGFRB and, 
NG_050964.1 and NM_004736.3 for XPR1.  
Copy number Variation (CNV). Quantitative multiplex PCR of short fluorescent fragments 
(QMPSF) was used to assess the presence of CNVs encompassing SLC20A2 and PDGFB, in 
the French and Brazilian series, as previously described.12,26 For the US series, CNVs were 
genotyped using TaqMan copy-number assays, following manufacturer’s instructions. 
Commercially available assays for the SLC20A2 (Hs00279506_cn, Hs00383415_cn), 
PDGFB (Hs00902096_cn and Hs01735391_cn) and PDGFRB (Hs01615581_cn, 
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Hs02279533_cn and Hs02258542_cn) genes were used. For the Italian series, the cn.MOPS 
tool was applied to next-generation sequencing data for CNV detection.27  
Variant assessment. Variant classification was conducted following ACMG-AMP 
recommendations.24 Briefly, these criteria included: prior identification as a PFBC-causing 
variant (reported in the literature, HGMD, Clinvar, and/or the PFBC variant database 
https://coppolalab.ucla.edu/lovd/genes), allele frequency in population databases (gnomAD,25 
http://gnomad.broadinstitute.org/), computational and predictive data (Polyphen 2, SIFT, 
MutationTaster, and splicing predictions provided by the Alamut visual software (Interactive 
biosoftware, Rouen, France)), functional studies (reported in the literature) and segregation 
data. Each variant was first classified into one of the 5 ACMG-AMP classes by an 
investigator from the group where it was identified, and then reviewed by the entire study 
group. All variants reported in this study were added to the PFBC database 
https://coppolalab.ucla.edu/lovd/genes. 
Affected relatives. Clinical and imaging data from affected relatives were collected, and 
genetic testing was performed on available DNA samples to ascertain variant cosegregation. 
 
RESULTS 
Genetic screening in the 4 series 
By screening the four known PFBC causative genes in 177 unrelated probands from 4 
independent international series, we identified 34 probands (19.2%) carrying a variant 
classified as pathogenic (class 5) or likely pathogenic (class 4), while 11 carried a variant of 
uncertain significance (VUS) (class 3, 6.2%). In contrast, CNV analysis did not reveal any 
clear large deletion or duplication in the PFBC genes screened. The overall variant detection 
rate was therefore 25.4% (45/177) (Supplementary Table 1). Only two out of the 177 
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unrelated probands were previously reported.23,28 After including 11 variant-carrying affected 
relative members, 56 individuals are described herein.  
 
SLC20A2 variants 
We identified 27 distinct SLC20A2 variants in 30 unrelated probands (16.9%, Table 1). Nine 
of these variants had previously been reported in other PFBC patients,3,4,6,7,29-32 including 6 
missense variants for which pathogenicity was uncertain, and that can now be classified as 
pathogenic: p.(Pro184Leu) and p.(Gly498Arg), or likely pathogenic: p.(Arg71His), 
p.(Asn194Ser), p.(Ser434Trp), and p.(Ala585Thr). These variants were seen in 12 of our 
unrelated probands, including the one case already reported in the literature.28 The remaining 
18 SLC20A2 variants were novel, of which 9 were protein-truncating variants (PTV) and 
were therefore classified as pathogenic.  
Two novel likely pathogenic variants were also identified. First, an in-frame deletion of 27 
nucleotides (c.1822_1848del) in exon 11 of SLC20A2 was identified in a proband and his 
affected father. This variant is predicted to cause a deletion of nine amino acids, 
p.(Ile608_Trp616del), at the C-terminal domain of Pit-2, in a transmembrane region. Second, 
a predicted-damaging missense variant, c.541C>T, p.(Arg181Trp) in exon 5 was identified in 
a patient and his affected father. This variant was found in one individual from the gnomAD 
database (MAF=4.1e-06). Other missense pathogenic variants in nearby residues have been 
reported in PFBC patients,4 supporting evidence for pathogenicity.  
Among the additional 7 novel VUS identified, 2 were intronic (c.289+5G>A, c.290-8A>G), 
absent from gnomAD and with strong in silico predictions of a splicing defect at the closest 
canonical site (MaxtEntScan score change of -80.7% and -54.4%, respectively, with the 
c.290-8A>G predicted to create a new acceptor site at position c.290-7). Two other novel 
missense VUS were located at exon boundaries. The c.290G>A, p.(Gly97Asp) variant, 
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affecting the first base of exon 3, was predicted damaging by in silico tools and to cause a 
slight effect in splicing (MaxEntScan score change: -7%). The c.1523G>A variant, 
p.(Ser508Asn), affecting the last base of exon 8, was also predicted to be damaging, in 
addition to a strong effect on splicing (MaxEntScan score change: -59.5%). RNA from these 
patients was not available to confirm the hypothesis of a protein truncating effect through 
altered splicing, precluding their classification as (likely) pathogenic. The other novel VUS, 
p.(His488Arg), p.(Gly589Arg) and p.(Val624Glu), were not detected in gnomAD and are 
predicted to be damaging by in silico analysis. Even though other missense pathogenic 
variants in nearby residues have been reported, there was not sufficient evidence to classify 




We identified 6 distinct PDGFB variants in 6 unrelated probands (3.4%, Table 2). Two of 
these variants had already been reported in other PFBC patients: nonsense p.(Arg149Ter) 
and, stop loss c.726G>C, p.(Ter242TyrExtTer89) that adds 89 residues to the protein.9 We 
identified a novel stop loss variant, c.724T>C, p.(Ter242GlnExtTer89), which is also 
predicted to cause an elongation of the reading frame by 89 amino acids. Functional studies 
have shown that proteins with variants causing a C-terminal extension, namely 
p.(Ter242TyrExtTer89), failed to induce any detectable PDGF-Rβ autophosphorylation.19 A 
novel canonical splice site variant, c.456+1G>A (Table 2), predicted to affect splicing of 
exon 4 in PDGFB, was identified in a proband and the affected mother. Both of these novel 
variants were absent from gnomAD. Therefore, there was enough evidence to support these 
variants as pathogenic for PFBC.  
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We also identified 2 novel missense variants, both absent from gnomAD and predicted 
damaging by in silico analysis: p.(Gly132Arg) and p.(Arg142His) (Table 2). Variant 
p.(Gly132Arg) was identified in an additional unrelated French patient with brain 
calcifications (enrolled after the data freeze, hence not included in this series) and was 
therefore classified as likely pathogenic.  
  
PDGFRB variants 
Three distinct PDGFRB variants were found in 3 unrelated probands (1.7%, Table 3): 
p.(Arg226Cys), p.(Pro596Leu) and p.(Asp844Gly), all novel missense variants, predicted 
damaging. Of these, only the p.(Pro596Leu) variant was present in 2 individuals in gnomAD 
(MAF=8.1e-06). Segregation data was only available for the family carrying the 
p.(Asp884Gly) variant and we showed that this variant resulted in a loss of PDGFRβ 
autophosphorylation (Supplementary Figure 1). Based on this evidence, this variant was 
classified as pathogenic, while the other two were classified as VUS. 
 
XPR1 variants 
Five distinct XPR1 variants were found in 6 unrelated probands (3.4%, Table 4). Two of 
these variants had already been associated with PFBC. One of our unrelated French patients 
carried the same p.(Leu145Pro) variant reported in the original XPR1 paper.22 The other 
variant, p.(Leu87Pro), was found in a case already reported.23 These two variants were not 
found in gnomAD and can be classified as pathogenic based on published functional 
evidence.22,23 Three additional predicted damaging missense variants were found (Table 4). 
While p.(Thr233Ser) was found in two unrelated PFBC individuals, it was also found in two 
individuals within the gnomAD database (MAF=8.1e-06). On the other hand, both 
p.(Arg459Cys) and p.(Asn619Asp) were not found in gnomAD. Furthermore, for 
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p.(Arg459Cys), the unaffected proband’s mother did not carry this variant and had a normal 
brain CT scan. Both p.(Thr233Ser) and p.(Arg459Cys) variants were therefore classified as 
likely pathogenic, while there was not sufficient evidences for p.(Asn619Asp), hence 
classified here as VUS. 
 
Clinical presentation 
Herein, we reported a total of 56 PFBC patients (32 F; 24 M), including the 45 probands that 
were found to carry VUS or (likely) pathogenic variants, and 11 relatives that had brain 
calcifications and the same variant as the proband (Figure 1A). Detailed clinical and 
radiological data were available in 54/56 patients (Tables 1-4), and at the time of genetic 
testing, 44 (81.5%) of these were symptomatic (Figure 1B). Mean age at clinical onset was 
47.2 years (Figure 1C)  (median = 52y, range: 3-81y, age at onset was unknown for 8 cases, 
including one with onset in childhood) and mean age at last examination was 57.4 years in 
symptomatic patients and 47.5 in asymptomatic patients. Parkinsonism (alone or combined 
with other clinical manifestations) was the most frequent finding, present in 24/44 (54.5%) of 
symptomatic patients, mostly with an akinetic-rigid presentation (Figure 1D). Cognitive 
impairment was documented in 19/44 (43.2%) symptomatic cases, as were psychiatric 
disturbances (depression, psychosis, anxiety), while 13/44 (29.5%) patients had cerebellar 
signs. In addition, migraine was reported by 10/54 patients (18.5%); in 5 of these patients 




We screened the four known PFBC causative genes in a series of 177 PFBC patients and 
identified 41 distinct variants, in a total of 45 unrelated probands. Taking into account only 
Ramos et al. 
likely pathogenic and pathogenic variants, for which evidence is sufficient to propose genetic 
counseling, 34 out of the 177 (19.2%) unrelated probands carried such variants. However, the 
overall variant detection rate can increase up to 25.4% (45/177), if future studies find new 
evidence to reclassify the VUS we found as causal. As expected, SLC20A2 showed the 
highest contribution with variants identified in 16.9% (30/177) of the probands, followed by 
XPR1 and PDGFB, each with 3.4% (6/177), and then PDGFRB with 1.7% (3/177). These 
rates are consistent with those reported in other French series that, similar to ours, had 
patients with and without known family history,33 in contrast to previous reports that showed 
high mutation rates in patients with a positive family history34. Even though we screened 
novel unrelated probands, we detected new but also previously reported PFBC variants, 
sometimes in patients originating from the same country as the original carrier. It should be 
noted that, based on available family information, none of the patients in our series seem to 
be related to any of the PFBC carriers already published in the literature. 
SLC20A2 was the first PFBC-causative gene to be identified, linking cerebral inorganic 
phosphate metabolism to PFBC’s pathophysiology.3 Evidence that SLC20A2 
haploinsufficiency causes PFBC is strong as both PTV and total/partial deletions have been 
identified.3,26,29 This hypothesis has been confirmed in mouse models,5,35,36 and by in vitro 
assessment of some of the missense variants.3 In our series, including patients with positive 
family history and apparently sporadic cases, we confirmed SLC20A2 as the major causative 
gene, accounting for at least 13.0% of the cases (adding up to 16.9% when including VUS). 
XPR1 was the most recent PFBC gene to be identified,22 and in our series, variants within 
these gene are as frequent as PDGFB variants. Pathogenicity of XPR1 variants reported to 
date has been ascertained based on: strong segregation22, recurrence among unrelated patients 
and/or functional data showing a defect in inorganic phosphate transport22,23. Interestingly, all 
known pathogenic variants are located in the SPX domain of XPR1, the function of which 
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remains uncertain. We identified 3 novel missense variants, all predicted damaging, but 
located outside the SPX domain. Functional analyses are needed to further clarify their role.  
The identification of protein-truncating PDGFB variants following the identification of 
missense PDGFRB variants, provided the first evidence that decreased PDGFB-PDGFRβ 
signaling was causative of PFBC. Loss-of-function and missense variants, as well as a partial 
PDGFB deletion have been identified to date,1,9,12,37 supporting haploinsufficiency as causal 
mechanism. Here, we report 4 novel variants, including one PTV, one stop loss and two 
missense variants, of which one could be classified as likely pathogenic. 
Since the original paper identifying PDGFRB as a PFBC causal gene, only 4 established 
pathogenic PDGFRB variants have been reported in the literature. These showed strong 
segregation evidence6 and/or functional evidence of a loss of protein function.8,19,20 Another 
missense variant, p.(Glu1071Val), originally considered as VUS has since been reclassified 
as likely benign based on functional studies.7,19,20 More recently, 2 novel variants were 
identified in Chinese PFBC cases: a c.3G>A variant leading to a loss of the start codon, and a 
missense p.(Asp737Asn) variant.38 Although the latter variant was considered a VUS, the 
start loss variant could be classified as pathogenic if considered truncating, however its 
functional effect remains unclear as an alternative in frame ATG codon could theoretically be 
used. Herein, we report 3 additional missense variants, though only one of them could be 
classified as pathogenic based on segregation and functional data.  
The PFBC phenotypic spectrum is wide and diverse, with intra and interfamilial 
heterogeneity. Although some of the variants found in this study are recurrent, their low 
frequency precluded any genotype-phenotype correlations, and therefore we focused on all 
carriers. We found that 81.5% of those with clinical information available were considered 
symptomatic, with severity ranging from minor signs on clinical examination to severe 
disability. In previous reports, including another French PFBC series and a meta-analysis 
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study, the proportion of symptomatic patients was indeed lower, 58% and 64%, 
respectively.1,39 Here, the relatively high proportion of symptomatic carriers is likely due to 
an inclusion bias, as symptomatic probands are more likely to be offered genetic screening 
than asymptomatic individuals and few relatives could be included in the present report 
(11/56 versus 35/57 in 1). Age of onset was comparable to previous screens, with a wide 
range from 3 to 81 years. Consistent with previously published series, the most frequent 
symptoms in our series were parkinsonism (54.5% of symptomatic individuals), cognitive 
impairment, and psychiatric signs (43.2% each). Interestingly, 18.5% of the 54 patients with 
available clinical data reported migraine without atypical features, which is in the same range 
as the general population,40 suggesting that migraine in patients with brain calcifications may 
be coincidental. This ratio is consistent with those reported in an independent series and a 
literature review study,1,39 while there are also reports that showed lack of segregation 
between brain calcification and migraine.41 
In summary, by screening the known PFBC genes in 4 cohorts from America and Europe, 
including sporadic and familial cases, we identified variants interpreted as VUS, likely 
pathogenic, or pathogenic in 25.4% of the 177 probands. While variants from the latter two 
classes can be used for genetic counseling, segregation and/or functional studies of the VUS 
are necessary to help clarify their role in PFBC, and therefore no presymptomatic testing can 
be recommended given the current level of evidence. The novel variants reported here will 
help with interpretation of future genetic screens of unrelated PFBC patients and provide a 
list of candidates for functional studies. Lastly, further prospective follow-up studies in 
patients carrying pathogenic variants in PFBC-related genes are needed to widen our 
knowledge about disease course, genetic and/or environmental factors which could influence 
disease penetrance and progression.  
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Table Legends: 
 
Table 1. Details on SLC20A2 variants and phenotype of variant carriers.  
AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate 
nuclei; Co: cerebral cortex; WM: subcortical white matter; Ver: vermis; NA: not available; 
DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: 
Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of Unknown 
Significance. Novel variant refers to variants that have not been previously reported in PFBC 
patients. gnomAD frequency, in parentheses is the maximal subpopulation frequency for 
Non-Finnish Europeans (NFE). Family history was considered positive if at least one first-
degree relative exhibited at least one neuropsychiatric symptom by interview. Variants were 
submitted to the https://coppolalab.ucla.edu/lovd_pfbc/genes/SLC20A2 database. Reference 
sequences: NG_032161.1 and NM_006749.4. 
Associated references: 4, 3, 6, 7, 28,29, 30, 31, 32  
 
Table 2. Details on PDGFB variants and phenotype of variant carriers.  
AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate 
nuclei; Co: cerebral cortex; WM: subcortical white matter; NA: not available; DC: Disease 
Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. 
ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of Unknown Significance. 
Novel variant refers to variants that have not been previously reported in PFBC patients. 
Family history was considered positive if at least one first-degree relative exhibited at least 
one neuropsychiatric symptom by interview. 
Variants were submitted to the https://coppolalab.ucla.edu/lovd_pfbc/genes/PDGFB 
database. Reference sequences: NG_012111.1 and NM_002608.2. 
Ramos et al. 
Associated reference: 9 
 
Table 3. Details on PDGFRB variants and phenotype of variant carriers.  
AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate 
nuclei; Co: cerebral cortex; WM: subcortical white matter; CBZ: carbamazepine; NA: not 
available; DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: 
Tolerated; D: Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of 
Unknown Significance. Novel variant refers to variants that have not been previously 
reported in PFBC patients. gnomAD frequency, in parentheses is the maximal subpopulation 
frequency for South Asians and Non-Finnish Europeans (NFE). Family history was 
considered positive if at least one first-degree relative exhibited at least one neuropsychiatric 
symptom by interview. 
* The PRRT2 and PNKD genes were sequenced in this patient and no change was detected. 
Variants were submitted to the https://coppolalab.ucla.edu/lovd_pfbc/genes/PDGFRB 
database. Reference sequence: NM_002609.3. 
 
Table 4. Details on XPR1 variants and phenotype of variant carriers.  
AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate 
nuclei; Co: cerebral cortex; WM: subcortical white matter; NA: not available; DC: Disease 
Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. 
ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of Unknown Significance. 
Novel variant refers to variants that have not been previously reported in PFBC patients. 
gnomAD frequency, in parentheses is the maximal subpopulation frequency for Non-Finnish 
Europeans (NFE). Family history was considered positive if at least one first-degree relative 
exhibited at least one neuropsychiatric symptom by interview. 
Ramos et al. 
Variants were submitted to the https://coppolalab.ucla.edu/lovd_pfbc/genes/XPR1 database. 
Reference sequence: NM_004736.3. 




Figure 1. Clinical presentation of 56 variant carriers. A. Number of familial (including 
relatives) and sporadic cases, and B. number of symptomatic and asymptomatic individuals 
per variant carrier. C. Distribution of age-at-onset (years) per gene carrier (horizontal line 
represents the average age of onset across all 37 cases with known age-at-onset). D. 
Frequency of main symptoms among the 44 symptomatic variant carriers.  
Ramos et al. 
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History CT scan  
1 EXT 1291 001 France Novel 5 Nonsense c.149T>G p.(Leu50Ter) 
Premature stop 




63 Negative Pa, Pu, WM, D 
2 IT-PFBC-7 Italy 32 4 Missense c.212G>A p.(Arg71His) 
Phosphate 
transporter  Absent DC (0.9) PD (1) D (0) Caucasian F Asymptomatic NA Negative Pa, Pu, Ca, T 
3 EXT 878 001 France Novel 3 
Predicted 
splicing c.289+5G>A p.? 
Predicted loss of 5' 
splicing donor site Absent  NA NA NA Caucasian F 
Pain, akinetic-
rigid syndrome 




Pa, Pu, Ca, 
D, T, Co, 
WM, Ver 
4 IT-PFBC-1 Italy Novel 3 
Predicted 
splicing c.290-8A>G p.? 
Predicted loss of 3' 
splicing acceptor 
site 




65 Negative Pa, Pu, D 
5 EXT 1132 001 France Novel 3 
Missense/ 
splicing? c.290G>A p.(Gly97Asp) 
First base of exon 
3, however splicing 
tools predict a 











18 Positive Pa, Pu, Ca, T, WM, Co 
6 Proband USA 28,29 5 Nonsense c.338C>G p.(Ser113Ter) 
Premature stop 
codon Absent DC (1) NA NA NA F NA NA Positive NA 




5 Nonsense c.338C>G p.(Ser113Ter) Premature stop codon Absent DC (1) NA NA Caucasian M 
Focal unilateral 
chorea (hand) 53 Negative 
Pa, Pu, Ca, 
T, D 












Pa, Pu, Ca, 



















Pa, Pu, Ca 





France 6 5 Missense c.551C>T p.(Pro184Leu) Cytoplasmic Absent DC (1) ?PD (0.98) D (0.05) Caucasian 
F Restless leg syndrome 55 
Positive 













F Asymptomatic (migraine) NA Pa, Pu, Ca, T 













Pa, Pu, Ca, 
D, T, Co, 
WM, Ver 
12 EXT 1180 001 France Novel 5 Splicing c.730+1G>T p.? 
Predicted skipping 
of exon 6 (in 
frame) or use of 
alternative splice 
site 










Italy Novel 5 Nonsense c.739C>T p.(Gln247Ter) Premature stop codon Absent DC (1) NA NA Caucasian 
F Asymptomatic NA 
Positive 











Pa, Pu, Ca, 
T, D, Co, 
WM 






Absent DC (1) NA NA Caucasian F Asymptomatic (migraine) NA Positive 
Pa, Pu, D, 
Co 

















(induced by L 
Dopa) 
51 Negative 
Pa, Pu, Ca, 




Brazil Novel 5 Frameshift c.1187dup  p.(Pro397AlafsTer18) 
Premature stop 
codon Absent DC (1) NA NA NA 
F Parkinsonism   NA 
Positive 
NA 
1B01BR M Stroke, aphasia, parkinsonism NA NA 
17 EXT 1083 001 France Novel 5 Nonsense c.1207C>T p.(Arg403Ter)
Premature stop 
codon Absent DC (1) NA NA Caucasian M 
Akinetic-rigid 
syndrome 65 Negative 
Pa, Pu, Ca, 
D, T, Co, 
WM, Ver 














3 Negative Pa, Pu, D 
19 EXT 1063 001 France Novel 5 Nonsense c.1426G>T p.(Glu476Ter)
Premature stop 







Pa, Pu, Ca, 
D, T, Co, 
WM, Ver 
20 IT-PFBC-3 Italy Novel 3 Missense c.1463A>G p.(His488Arg)
Phosphate 
transporter  Absent DC (0.99) B (0,005) 
T 






59 Negative Pa, Pu 
21 Proband USA 3 5 Missense c.1492G>A p.(Gly498Arg) 
Phosphate 
transporter  Absent DC (0.99) PD (0.994) 
D 





muscle tone and 
pain. 





Italy 3 5 Missense c.1492G>A p.(Gly498Arg) 
Phosphate 






Pa, Pu, Ca, 





F Asymptomatic NA  Pa, Pu 
23 EXT 1136 001 France Novel 5 Splicing c.1524-2A>G p.? 
Predicted skipping 
of exon 9 (in 
frame) or use of 
alternative splice 
site 









71 Negative Pa, Pu, Ca, T, D, Ve, Co 
24 EXT 1318 001 France Novel 3 
Missense / 
Splicing c.1523G>A p.(Ser508Asn)
Last base of exon 
8; splicing tools 
predict a major 
effect on splicing 
(MaxEntScan score 
change:-59.5%)  
Absent DC PD D  Caribbean F 
















codon Absent  NA NA Caucasian F 
Migraine, 
vestibular signs NA Positive Pa, Pu, Ca, T 
26 EXT 1235 001 France 4 4 Missense c.1753G>A p.(Ala585Thr)
Phosphate 
transporter  Absent DC PD T  African F 
Dementia and 
Parkinsonism NA Negative 
Pa, Pu, T, 
Ca, D, Co 






codon Absent NA NA NA Caucasian M 









3 Positive Pa, Pu, Ca, T, D, T, Co 
28 IT-PFBC-4 Italy Novel  3 Missense c.1765G>A p.Gly589Arg 
Phosphate 
transporter  Absent DC (0.99) PD (0.99) 
D 
(0.01) Caucasian F Dementia 81 Positive  Pa, D 
29 
Proband 









transporter  Absent NA NA NA Caucasian 
M ADHD NA 
Positive 
Pa, Pu, Ca, 
T, Co 
Father M Anxiety, dystonia NA Pa 
30 EXT 1020 001 France Novel 3 Missense c.1871T>A p.(Val624Glu)
Phosphate 




(0.15) Caucasian M 








age 7, is also 
present in two 
sibpairs in the 
absence ofbrain 
calcification 
7 Negative  Pa, Pu, D, WM 
Table 1. Details on SLC20A2 variants and phenotype of variant carriers. AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate nuclei; Co: cerebral cortex; WM: subcortical 
white matter; Ver: vermis; NA: not available; DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant 
of Unknown Significance. Novel variant refers to variants that have not been previously reported in PFBC patients. gnomAD frequency, in parentheses is the maximal subpopulation frequency for Non-Finnish 
Europeans (NFE).  Family history was considered positive if at least one first-degree relative exhibited at least one neuropsychiatric symptom by interview. 
Variants were submitted to the https://coppolalab.ucla.edu/lovd_pfbc/genes/SLC20A2 database. Reference sequences: NG_032161.1 and NM_006749.4. 
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gnomAD Mutation Taster 
Polyphen




History CT scan  
31 EXT 929 001 France Novel 4 Missense c.394G>C 
p.(Gly132Arg
) PDGF domain Absent DC (1) PD (1) D (0) Caucasian F Asymptomatic NA 
Negativ
e Pa, Pu, D 
32 ROU  1184 001 France Novel 3 Missense c.425G>A p.(Arg142His) PDGF domain Absent DC (0.97) PD (1) 
T 
(0.33) Caucasian F 
Personality disorder, 




syndrome, pyramidal signs, 
gait disorder, frontal 
behavioral disorder 
68 Negative Pa, Pu, D 
33 EXT  1196 001 France 9 5 Nonsense c.445C>T p.(Arg149Ter)
Premature stop 
codon Absent DC (1) NA NA Caucasian M 
Dysexecutive syndrome 




44 Positive Pa, Pu, Ca, D, T (MR) 
34 
Proband 






Absent NA NA NA NA 
F Severe migraine, history of depression 20 
Positive 
Pa, Pu, Ca, 
WM, D, Co 
Mother F Migraine, history of depression 26 
Pa, Pu, Ca, 
T, D, WM 




protein, loss of 
function 






Pa, Pu, Ca, 
D (MRI) 




protein, loss of 
function 
Absent NA NA NA Caucasian M 
Orofacial dyskinesia, oral 
tics, pyramidal signs, 
alcohol abuse, comorbid 
aneurysm of the right medial 
cerebral artery 
NA Positive 
Pa, Pu, Ca, 
D, T, Co, 
WM 
Table 2. Details on PDGFB variants and phenotype of variant carriers. AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate nuclei; Co: cerebral cortex; WM: subcortical 
white matter; NA: not available; DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of Unknown 
Significance. Novel variant refers to variants that have not been previously reported in PFBC patients. Family history was considered positive if at least one first-degree relative exhibited at least one neuropsychiatric 
symptom by interview. 
























History CT scan  












Pa, Pu, Ca, 
T, D 












DC PD (1) D (0) Caucasian F Asymptomatic (migraine) NA 
Negativ
e Pa, Pu 
39 
Proband 




Absent DC (0.99) PD (0.998) D (0.01) Caucasian 





aunt F NA NA NA 
Table 3. Details on PDGFRB variants and phenotype of variant carriers. AAO: age at onset; Pa: pallidum; Pu: putamen; Ca: caudate nuclei; T: thalamus; D: dentate nuclei; Co: cerebral cortex; WM: subcortical 
white matter; CBZ: carbamazepine; NA: not available; DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - 
Variant of Unknown Significance. Novel variant refers to variants that have not been previously reported in PFBC patients. gnomAD frequency, in parentheses is the maximal subpopulation frequency for South Asians 
andNon-Finnish Europeans (NFE). Family history was considered positive if at least one first-degree relative exhibited at least one neuropsychiatric symptom by interview. 
* The PRRT2 and PNKD genes were sequenced in this patient and no change was detected. 
















gnomAD Mutation Taster 
Polyphe
n2 SIFT Ethnicity Sex Clinical summary AAO 
Family 



















Pa, Pu, Ca, 















Pa, Pu, Ca, 





F Bradykinesia, psychomotor slowing 38 
Pa, Pu, Ca, 





Italy Novel 4 Missense c.697A>T p.(Thr233Ser) 










(0.03) Caucasian F 
Mild Cognitive 





Italy Novel 4 Missense c.697A>T p.(Thr233Ser) 













France Novel 4 Missense c.1375C>T p.(Arg459Cys) 
outside from SPX 










France Novel 3 Missense c.1855A>G p.(Asn619Asp) 
outside from SPX 
domain Absent DC (1) PD (1) D (0) Caucasian M 
Sudden deafness, mild 
cerebellar syndrome 69 Positive 
Pa, Pu, Ca, 
D, T 
Table 4. Details on XPR1 variants and phenotype of variant carriers. AAO: age at onset; Pa: pallidum; Pu: putamen; Ca:. caudate nuclei; T: thalamus; D: dentate nuclei; Co: cerebral cortex; WM: subcortical white 
matter; NA: not available; DC: Disease Causing; PossD: Possibly damaging; PD: Probably Damaging; T: Tolerated; D: Deleterious. ACMG class: 5 - Pathogenic, 4 - Likely Pathogenic, 3 - Variant of Unknown 
Significance. Novel variant refers to variants that have not been previously reported in PFBC patients. gnomAD frequency, in parentheses is the maximal subpopulation frequency for Non-Finnish Europeans (NFE). 
Family history was considered positive if at least one first-degree relative exhibited at least one neuropsychiatric symptom by interview. 
Variants were submitted to the following database; https://coppolalab.ucla.edu/lovd_pfbc/genes/XPR1 database. Reference sequence: NM_004736.3. 
 
